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Background: Hemoglobin is the major protein found in erythrocytes, where it acts as an
oxygen carrier molecule. In recent years, its expression has been reported also in neurons
and glial cells, although its role in brain tissue remains still unknown. Altered hemoglobin
expression has been associated with various neurodegenerative disorders. Here, we
investigated hemoglobin mRNA levels in brains of patients affected by variant, iatrogenic,
and sporadic forms of Creutzfeldt-Jakob disease (vCJD, iCJD, sCJD, respectively) and
in different genetic forms of prion diseases (gPrD) in comparison to Alzheimer’s disease
(AD) subjects and age-matched controls.
Methods: Total RNA was obtained from the frontal cortex of vCJD (n = 20), iCJD
(n = 11), sCJD (n = 23), gPrD (n = 30), and AD (n = 14) patients and age-matched
controls (n = 30). RT-qPCR was performed for hemoglobin transcripts HBB and
HBA1/2 using four reference genes for normalization. In addition, expression analysis
of the specific erythrocyte marker ALAS2 was performed in order to account for blood
contamination of the tissue samples. Hba1/2 and Hbb protein expression was then
investigated with immunofluorescence and confocal microscope analysis.
Results: We observed a significant up-regulation of HBA1/2 in vCJD brains together
with a significant down-regulation of HBB in iCJD. In addition, while in sporadic and
genetic forms of prion disease hemoglobin transcripts did not shown any alterations,
both chains display a strong down-regulation in AD brains. These results were confirmed
also at a protein level.
Conclusions: These data indicate distinct hemoglobin transcriptional responses
depending on the specific alterations occurring in different neurodegenerative diseases.
In particular, the initial site of misfolding event (central nervous system vs. peripheral
tissue)—together with specific molecular and conformational features of the pathological
agent of the disease—seem to dictate the peculiar hemoglobin dysregulation found in
prion and non-prion neurodegenerative disorders.
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In addition, these results suggest that gene expression of HBB and HBA1/2 in brain
tissue is differentially affected by distinct prion and prion-like aggregating protein strains.
Validation of these results in more accessible tissues could prompt the development of
novel diagnostic tests for neurodegenerative disorders.
Keywords: hemoglobin, prion, RT-qPCR, Alzheimer’s disease, vCJD, neurodegeneration
INTRODUCTION
Neurodegenerative diseases are incurable debilitating disorders
of the nervous system, characterized by structural and functional
neuronal loss. Approximately 30 million people are affected
worldwide, and this number is predicted to reach more than 100
million by 2050 (Benetti et al., 2012).
These disorders, which include Alzheimer’s, Parkinson’s,
and prion diseases among others, are characterized by the
accumulation of aggregated proteins in the form of amyloid,
often associated to pathological lesions (Jucker and Walker,
2013). The aggregation of amyloidogenic proteins can result
either in a gain of toxic functions, derived from the damage
provoked by these deposits in affected tissue, or in a loss of
functions, due to the sequestration and the consequent inability
of the aggregating protein to ensure its physiological role.
Prion diseases etiology can be sporadic, infectious or genetic,
with the various forms of Creutzfeldt-Jakob Disease (CJD)—
sporadic, familial, variant, and iatrogenic—being the most
common prion disorder in humans. Genetic diseases include
Gerstmann–Straussler–Scheinker (GSS) and Fatal Familial
Insomnia (FFI). Pathological hallmarks include spongiform
vacuolation in brain tissue, neuronal loss, microglial activation
and astrocytes proliferation, together with the intracerebral
accumulation of the protease-resistant form of the prion protein
(PrPSc).
More than three decades ago, globin-related mRNAs were
reported in the mouse brain (Ono and Cutler, 1978). In 2009,
the finding of α and β hemoglobin transcripts in substantia nigra
neurons of mesencephalic dopaminergic cell system (Biagioli
et al., 2009) opened the doors to an unexplored field of
research. In particular, hemoglobin expression in mice and
human neurons has been validated both at transcriptional
and protein levels (Richter et al., 2009; Brown et al., 2016),
while its glial expression remains unclear (Richter et al., 2009;
Schelshorn et al., 2009; Chuang et al., 2012). Indeed, a decrease,
sometimes an absence, of hemoglobin expression in neurons
containing neurofibrillary tangles (NFTs), pre-tangles, and α-
synuclein deposits in Alzheimer’s disease (AD), argyrophilic
grain disease (AGD), and dementia with Lewy bodies (DLB)
brains, respectively, has been reported (Ferrer et al., 2011).
The function of neuronal hemoglobin (nHb) is still debated.
Its ability to bind molecular oxygen is effective for the precise
regulation of O2 homeostasis required in neurons (Ohyagi et al.,
1994). In particular, while erythrocyte hemoglobin is known to
be responsible of O2 delivery to body tissues, its brain tissue
expression could be related to facilitation of O2 uptake into
neurons, acting as an oxygen capacitor molecule (Schelshorn
et al., 2009). The role of Hb in neuronal oxygen homeostasis
is supported by the finding that its canonical α2β2 tetrameric
structure, necessary for O2 coordination, is maintained also in
neurons (Russo et al., 2013).
Neurons are metabolically active cells, therefore mitochondria
are essential for their physiology. Hb involvement in
mitochondrial respiration and regulation of the redox system is
supported by several findings in literature (Biagioli et al., 2009;
Brown et al., 2016). In particular, a strong down-regulation of
hemoglobin α, adult chain 2, and β chains mRNA has been
reported in neurons of rat treated with rotenone, an inhibitor of
complex 1 of the mitochondrial respiratory chain (Richter et al.,
2009).
Since iron is essential for hemoglobin oxygen transport,
altered neuronal levels of α and β chains corroborates the
hypothesis of a disruption in iron homeostasis, found in sCJD,
AD, and PD brains, as one of the key feature at the basis of
neurodegeneration (Singh, 2014).
Thanks to iron-containing heme, Hb is able to interact also
with amyloid-β (Aβ), promoting its aggregation (Wu et al., 2004;
Chuang et al., 2012). Double immunofluorescent assay on AD
brain patients, revealed co-localization of hemoglobin and Aβ
in senile plaques and cerebral amyloid angiopathy, suggesting
hemoglobin involvement in AD pathology (Wu et al., 2004).
In prion diseases, some evidence exists for hemoglobin
involvement in different animal models. Hba-a1 and Hbb-y
were found down-regulated both in the preclinical and clinical
phase in the CNS of scrapie-infected mice (Booth et al., 2004a).
Furthermore, down-regulation of HBB and HBA2 expression
levels in late stage of intracranially BSE-infected macaques
(Barbisin et al., 2014) andHBA2 down-regulation in the blood of
preclinical atypical BSE-infected cattle (Xerxa et al., 2016) suggest
an involvement of hemoglobin genes in the host response to BSE
prion strain infection.
In the present study, we decided to investigate the hemoglobin
genes expression in a wide variety of human prion diseases, with
the aim to shed light on the role of different prion strains and
routes of infections on the hemoglobin regulation.
MATERIALS AND METHODS
Ethics Statement
All samples were collected according to the ethical and safety
regulations of the Countries in which samples were collected, and
with the approval of the local ethics committees.
Human biological samples and associated data were obtained
from the Austrian CJD Surveillance and KIN-Biobank Medical
University of Vienna (Austria), the MRC Edinburgh Brain
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Bank (UK), the Institute of Neuropathology Brain Bank (HUB-
ICO-IDIBELL Biobank) (Barcelona, Spain), the French National
Neuropathological Network for CJD and the French National
Centre of Reference for prions (France), the Carlo Besta
Neurological Institute (Milan, Italy) and the University hospital
of Verona (Italy).
Informed and written consent for the research use of autopsy
tissue was obtained from the relatives of the deceased whenever
necessary in accordance with the Declaration of Helsinki (1964–
2008) and the Additional Protocol on the Convention of Human
Rights and Biomedicine concerning Biomedical Research (2005).
PRNP gene was analyzed pre-mortem in all cases with the
informed and signed consent of the patient’s family.
Patient Samples
The study was performed on samples coming from the following
cases: AD (n= 14) Braak stages I-III, sCJD (n= 23), genetic prion
diseases gPrD (n = 30), vCJD (n = 20), and iCJD (n = 11). Age-
matched subjects died from unrelated conditions and lacking
any neurological sign and with no pathological lesions in brain
were included as controls (n = 30). Prion disease cases were all
confirmed by means of Western Blot and/or PRNP sequencing,
while AD diagnoses were confirmed through neuropathological
analysis.
The full list of samples and patient details is reported
elsewhere (Vanni et al., 2017). Blood samples (n = 4) were
obtained by Carlo Besta Neurological Institute (Milan, Italy).
Tissue and RNA Extraction
Total RNA from frozen frontal cortex was extracted with
PureLink RNA Mini Kit (Life Technologies) and on-column
DNA digestion. Blood samples were collected in PAXgene Blood
RNA Tubes (Qiagen) and the related RNA was extracted using
PAXgene Blood RNA Kit (Qiagen). RNA integrity was analyzed
using 2100 Bioanalyzer (Agilent Technologies). Samples included
in our gene expression analysis displayed RNA Integrity Number
(RIN) ≥ 4, with the exception of few rare samples.
Reverse Transcription and Real
Time-Quantitative PCR (RT-qPCR)
For frontal cortex, cDNA was obtained from 3 µg of total
RNA with 50µM Oligo(dT)20, 10mM dNTP mix, 5X First
Strand Buffer, 0.1M DTT, 40U RNAse inhibitor, and 200U
SuperScript R© III Reverse Transcriptase (Life Technologies).
cDNA from blood samples was obtained using 750 ng RNA, with
the same reaction conditions as above. For each sample a negative
control was performed by omission of the reverse transcriptase
(-RT control). Specific qPCR primers were designed using the
online tool Primer-Blast provided by NCBI.
The primers sequences were as follows: for GAPDH 5′-CCT
GCACCACCAACTGCTTA-3′ and 5′-TCTTCTGGGTGGCAG
TGGATG-3′; for ACTB 5′-AGAGCTACGAGCTGCCTGAC-3′
and 5′-AGCACTGTGTTGGCGTACAG-3′; for RPL19 5′-CTAG
TGTCCTCCGCTGTGG-3′ and 5′-AAGGTGTTTTTCCGGCA
TC-3′; B2M for 5′-AGATGAGTATGCCTGCCGTG-3′ and 5′-T
CATCCAATCCAAATGCGGGC-3′; for HBB 5′-AGGAGAAGT
CTGCCGTTACTG3′ and 5′-CCGAGCACTTTCTTGCCATGA-
3′; forHBA1/2 5′-TTCTGGTCCCCACAGACTCA-3′ and 5′-CA
GGAACATCCTCTCCAGGG-3′; for ALAS2 5′-TGTCCGTCTG
GTGTAGTAATGA-3′ and 5′-GCTCAAGCTCCACATGAAAC
T-3′; for KDR 5′-GACCGGCTGAAGCTAGGTAA-3′ and 5′-CG
ATGCTCACTGTGTGTTGC-3′; for CD34 5′-ACCACTAGCAC
TAGCCTTGC-3′ and 5′-GGCAGATGCCCTGAGTCAAT-3′.
Gene expression assays were performed using iQTM SYBR R©
Green Supermix 2x (Bio-Rad Laboratories, Inc.), 400 nM final
concentration of the corresponding forward and reverse primer
(Sigma) and 10 ng/µL final concentration of cDNA samples, with
CFX96 TouchTM Real-Time PCR Detection System (Bio-Rad
Laboratories, Inc.).
RT-qPCR Data Analysis
Differential expression of target genes was normalized to four
reference genes (GAPDH, ACTB, RPL19, and B2M) expression.
Initially, the absolute expression value (CT) of a specific
erythrocyte marker, ALAS2, was used to exclude blood
contaminated samples and the relative expression ratio (fold
change, FC) was calculated using the 2 −11CT method (Livak and
Schmittgen, 2001).
Then, an additional normalization was performed using
ALAS2 expression values, to take into account the blood
contamination of each brain tissue sample.
The “blood normalized” FC was calculated using the
2−11CT method corrected for erythrocytes marker expression, as
following:
1CT (“blood normalized” test) = (CT(target, test) − CT(reference, test))
− CT(erythrocyte marker, test).
1CT(“blood normalized” calibrator) = (CT(target, calibrator)
− CT(reference, calibrator))
− CT(erythrocyte marker, calibrator).
11CT(“blood normalized”) = 1CT(“blood normalized” test)
−1CT (“blood normalized” calibrator).
FC = 2−11CT (“blood normalized”).
1CT were calculated subtracting the CT of the housekeeping
gene to the CT of the target one, both for “test” (disease affected
patient) and “calibrator” (control). Then, 11CT was calculated
subtracting the average 1CT of age-matched control groups to
the average1CT of each disease groups.
To select age-matched control for each prion diseases and
Alzheimer’s disease group, the same sample size of non-
neurodegenerative controls was chosen to match both median
and average age of disease affected patients’ group.
Fold change values smaller than 1 were converted using the
equation-1/fold change, for ease of representation.
Validation of “Blood Normalization”
Analysis Method
In order to prove the robustness of the proposed method,
we performed additional analysis as validation. We performed
spiking experiments adding increasing concentrations of blood
cDNA (from 0.1 pg to 1 ng, corresponding to four orders of
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magnitude) to a fixed amount of “contaminated” brain cDNA
(10 ng, the same used in all our qPCR experiments). The
validation experiments were carried out using blood samples
from two healthy controls and two patients.
In these mixed samples, we analyzed the levels of HBB,
HBA1/2, ALAS2 and the four reference genes that we mentioned
above.
Statistical Analysis
Test-F was used to verify the homoscedasticity of variance
between 1CTs of disease-affected and the related age-matched
control group (α = 0.05). Level of significance was calculated
using unpaired student t-test (two tails, p < 0.05) between 1CTs
of disease and control groups. Correlation was calculated using
Pearson correlation equation (R).
Double-Labeling Immunofluorescence and
Confocal Microscopy
De-waxed sections, 4 microns thick, corresponding to cortical
layer III, were stained with a saturated solution of Sudan
black B (Merck, DE) for 15min to block the autofluorescence
of lipofuscin granules present in cell bodies, and then rinsed
in 70% ethanol and washed in distilled water. The sections
were incubated at 4◦C overnight with mouse monoclonal
anti-hemoglobin-α (1:50, Santa Cruz, TX, USA) or rabbit
polyclonal anti-hemoglobin-β (1:50, Abcam, UK), and rabbit
polyclonal antibody anti-GFAP (1:400, Diagnostic Biosystem,
Barcelona, Spain) or mouse monoclonal anti-NeuN (1:100,
Merck Millipore, MA, USA), respectively. After washing, the
sections were incubated with Alexa488 (1:400, Molecular Probes,
USA) fluorescence secondary antibodies. Nuclei were stained
with DRAQ5TM (1:2,000, Biostatus, GB). After washing, the
sections were mounted in Immuno-Fluore mounting medium
(ICN Biomedicals, USA), sealed, and dried overnight. Sections
were examined with a Leica TCS-SL confocal microscope.
Data Availability
All data generated and/or analyzed during the current study are
available from the corresponding author on reasonable request.
RESULTS
qPCR Analysis
We obtained a list of 128 suitable samples, grouped as reported
in Table 1. In general RNA integrity is a common issue when
dealing with post-mortem tissue. Indeed, it is known to depend
on several variables such as prolonged storage (Schoor et al.,
2003), unrefrigerated post-mortem interval (Weis et al., 2007)
and deterioration associated to brain acidosis during prolonged
agony before death (Koppelkamm et al., 2011; Wang et al.,
2012). After stringent RNA quality assessment, almost half of the
collected samples displayed a high degree of degradation (RIN<
4) that did not allow their use in this study.
Complementary DNA was obtained by reverse transcription
from the selected RNAs. Then, samples from patients and
controls were analyzed by qPCR in parallel, to avoid bias due to
samples handling.
TABLE 1 | Summary of sample groups used in the study.
Group Number (n =) Mean age (ys ± SD)
CTRL 30 –
sCJD 23 67 ± 13
gPrD 30 54 ± 12
vCJD 20 35 ± 13
iCJD 11 29 ± 5
AD 14 69 ± 10
To select age-matched controls for each prion diseases and Alzheimer’s disease groups,
the same sample size of non-neurodegenerative controls was chosen to match both
median and average age of disease affected patients’ group.
It is known that normalization by an internal reference gene
reduces tissue derived effects on RT-qPCR (Fleige and Pfaﬄ,
2006). The vast majority of RT-qPCR expression profiles found
in the literature uses GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) as a reference gene for normalization (Penna
et al., 2011). However, ACTB (actin-β), B2M (β2-microglobulin),
and the ribosomal protein family seem to show good stability
across different RIN-values (Koppelkamm et al., 2011) and brain
samples (Penna et al., 2011). Therefore, we decided to use
GAPDH, ACTB, RPL19, and B2M as references to normalize RT-
qPCR data in order to consolidate the relative gene expression
levels, given the high variability characterizing human samples.
First, the four housekeeping genes were analyzed across
diseased and control cases in order to assess their expression
stability (Figure 1).
As shown, all four genes selected for reference displayed
comparable expression levels across all the analyzed groups, with
very similar CT-values and standard deviation both within and
across each group.
Hemoglobin is the major protein found in erythrocytes, and
besides its high concentration at protein level, high amount of Hb
transcripts were found in erythrocytes (Gotting and Nikinmaa,
2015). Therefore, we decided to perform a titration using serial
dilution of blood tissue, comparing their Hb expression levels to
one present in brain tissue, in order to understand how much
the contaminating blood would affect our results related to brain
tissue.
First, we observed that both HBB and HBA1/2 expression was
higher than reference genes in blood samples, highlighting the
presence of a large amounts of Hb transcript within blood cells.
Furthermore, we found that Hb transcripts are highly expressed
even in very small amount of blood samples (CT = 17 for HBB
and CT = 20 for HBA1/2) when compared to their expression
levels in brain tissue (Figure S1).
In light of these results, dealing with material in which blood
contamination is inevitable, we decided to analyze the expression
levels of the erythrocyte marker, ALAS2, in order to account for
the blood influence on the expression of our target genes.
The absolute quantification of ALAS2 was previously used
as threshold to exclude blood contaminated samples from gene
expression analysis (Barbisin et al., 2014). However, the vast
majority of our samples presented small blood traces as we
inferred from CTs ≤ 35 for ALAS2 (Figure 2). Thus, we decided
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FIGURE 1 | Comparison between GAPDH, ACTB, RPL19, and B2M stability
across controls and patients. For each group, average values of absolute CTs
among the samples are shown. Each sample was analyzed in triplicates.
to exclude samples showing CT ≤ 30 for ALAS2, considering
them as the ones with blood contamination, which could sensibly
influence the reliability of results, related to the regulation of both
hemoglobin chains.
ThemRNA levels of the selected human frontal cortex samples
were calculated using the 2−11CT method. No significant
dysregulation among the different diseases patient’s groups, when
compared to age-matched controls, was evident. In particular, FC
≤ 2 were observed for bothHBB andHBA1/2 after normalization
vs. all four housekeeping genes, with opposite trend between the
two chains in most of groups, making difficult to obtain reliable
conclusions (data not shown).
One other source of contamination of Hb transcripts would
be the endothelium, especially for HBA1/2 gene, which has been
previously reported to be well expressed in endothelial cells.
Since neither AD nor prion diseases are known for alterations
in the number of vessels, the influence of endothelial Hb should
be similar across controls and patients. However, to better
address this point we tested seven commonly known endothelial
and/or angiogenesis markers (ICAM1, vWF, PECAM1, KDR,
CD34, TEK, and CDH5) on brain cDNA (10 ng) and blood
cDNA (10 ng) and found out that only two of them were
not detectable in blood (data not shown). Then, we performed
qPCR analysis for KDR and CD34 (Hirakawa et al., 2003) in
AD and control samples and we did not detect any significant
difference between the groups (Figure 3). Therefore, even if we
are not able to quantify the precise influence of endothelial cells
on our results, we are pretty confident that this would affect
equally controls and diseased samples without impairing our final
results.
Blood-Normalized Gene Expression
Analysis
The high hemoglobin genes expression we observed in blood
(Figure S1), in line with previous findings (Gotting and
Nikinmaa, 2015), suggested us that even minute blood traces
could influence brain hemoglobin gene expression. Therefore,
we wondered if the inconclusive results obtained performing the
2−11CT analyses might have been jeopardized by the blood traces
not taken in consideration by the ALAS2 CT cutoff value (CT ≤
30) used to exclude blood-contaminated samples.
We also show that besides hemoglobin, reference genes are
highly expressed in very small amounts of blood (Figure S1),
suggesting that hemoglobin genes expression levels in brain could
be influenced also by the different expression of housekeeping
genes among tissues.
Therefore, we decided to include the expression level (CT)
of ALAS2 in 1CT formula in order to normalize the gene
expression of both targets and housekeeping genes for each single
sample on its specific blood content. Furthermore, we decided
to re-introduce the previously excluded blood contaminated
samples. In order to validate the robustness and efficacy of our
correction method, we performed several spiking experiments
adding different amounts of blood cDNA to the same amount of
brain cDNA. As showed,ALAS2 expression is decreasing with the
reduction of blood added to the brain, in the very same manner
as HBB and HBA1/2, confirming its specificity as blood marker
(Figures S2, S3). We analyzed the correlation between the relative
expression of ALAS2 and HBB (Figure 4) or HBA1/2 (Figure 5),
and the resulting r-values were 0.99989 and 0.99997, respectively.
Importantly, when we then analyzed the same samples
with our blood-normalized method, the expression levels of
both HBB and HBA1/2 of all samples containing increasing
amounts of blood were comparable to the one of the
brain alone (Figures S2, S3), with FC lying between 1 and
2, where FC ≥ 2 is commonly used as the threshold for
defining an upregulation, especially for highly heterogeneous
samples as human ones. We obtained similar results
normalizing the data against ACTB, RPL19, and B2M (data
not shown).
This modified RT-qPCR data analysis method revealed
significant dysregulation of both hemoglobin gene chains in some
groups, with very similar results normalizing targets to all four
reference genes (Figure 6, Figures S4–S6).
While in genetic prion diseases and sporadic CJD groupsHBB
and HBA1/2 expression levels did not show any dysregulation,
in AD patients both hemoglobin transcripts were strongly down-
regulated. Given that in literature is well known that gender plays
an important role in AD occurrence, the control group was both
age- and sex-matched (Figure S7 and Table S1), even though we
did not observe any age- or sex-related variability neither inHBB
nor in HBA1/2 (Figures S8, S9).
Concerning acquired prion diseases, iCJD patients exhibited
a down-regulation of both chains as well, even if statistical
significance was reached only for HBB. On the contrary, vCJD
patients showed an up-regulation of Hb transcripts, which was
significant for HBA1/2 (Figure 6).
Similar results were obtained normalizing data against all the
other three reference genes (Figures S4–S6).
Immunofluorescence and Confocal
Microscopy Analysis
Immunofluorescence and confocal microscopy analysis was
performed on AD and sCJD frontal cortex slices. We observed
that both Hb β and Hb α immunoreactivity is reduced in
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FIGURE 2 | Blood erythrocyte markers expression across controls and patients. Absolute CT-values for ALAS2 in control and neurodegenerative affected brain
samples. “Blood contaminated” samples are shown in red. Pool of blood cDNA (n = 2) is used as positive control (in red).
FIGURE 3 | Endothelial markers expression levels in AD patients. Relative
expression levels of CD34 and KDR normalized against GAPDH in AD patients
vs. age-matched controls, with related p-values. For FC-values smaller than 1
the reciprocal (−1/FC) is reported, for ease of representation.
neurons in ADwhen compared to control samples, recapitulating
the results observed at the transcriptional level (Figures 7, 8).
Concerning sCJD slices, we observed a slight decrease of
Hb β immunoreactivity in neurons, mirroring the trend of
the mRNA expression (Figure 7). In contrast, Hb α neuronal
immunoreactivity was preserved or increased when compared
to controls (Figure 8). Hemoglobin immunoreactivity was barely
observed in astroglia, excepting one single case in which
immunoreactivity for hemoglobin α-chain, but not β-chain, was
evident in astrocytes (Figures S10, S11).
DISCUSSION
In recent years, hemoglobin genes and protein dysregulation
has been associated with several neurodegenerative diseases in
humans, including AD, PD, MSA, MS (Broadwater et al., 2011;
FIGURE 4 | Correlation between HBB and ALAS2 expression in brain samples
(pool of 2 AD samples) containing serially diluted amounts of blood cDNA (pool
of 2 healthy controls and 2 patients). R, Pearson correlation coefficient.
Ferrer et al., 2011; Shephard et al., 2014; Brown et al., 2016; Mills
et al., 2016), andwith prion disease inmouse (Booth et al., 2004a),
macaque (Barbisin et al., 2014), and cattle models (Xerxa et al.,
2016).
To better understand the hemoglobin genes involvement
in human prion disorders, we investigated their expression
levels across different prion diseases, either sporadic acquired or
genetic.
In mammalian enucleated erythrocytes, the α and β chains
forming hemoglobin are present at high concentrations, resulting
in an efficient O2 transport mechanism (Schechter, 2008).
However, Hb chains have been detected also in a plethora of non-
erythroid cells including neurons and glial cells (Biagioli et al.,
2009).
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FIGURE 5 | Correlation between HBA1/2 and ALAS2 expression in brain
samples (pool of 2 AD samples) containing serially diluted amounts of blood
cDNA (pool of 2 healthy controls and 2 patients). R, Pearson correlation
coefficient.
FIGURE 6 | Blood-normalized HBB and HBA1/2 expression. Relative
expression levels of HBB and HBA1/2 against GAPDH and against ALAS2 in
gPrD, sCJD, vCJD, iCJD, and AD patients. *p < 0.05, **p < 0.005.
As a first step, based on active transcription within
human red blood cells (Kabanova et al., 2009) and, more
importantly, given that Hb transcripts are present at high
levels in mammalian mature circulating erythrocytes (Gotting
and Nikinmaa, 2015), we hypothesized that the presence of
blood in human frontal cortex could potentially jeopardize
hemoglobin gene expression dysregulation. In addition, Wu and
colleagues suggested that cerebral blood supply could represent
another source of brain hemoglobin. For example, the commonly
observed AD cerebrovascular lesions induce transient infiltration
of erythrocytes from circulation into the brain parenchyma, thus
influencing hemoglobin levels (Wu et al., 2004).
Only few studies concerning Hb dysregulation in
neurodegenerative-affected patients have considered red blood
cells (RBCs) hemoglobin contribution. Tissue contamination
with RBCs could influence the neuronal/glial hemoglobin
expression analysis. Ferrer and colleagues reported neuronal
hemoglobin to be reduced in AD and other neurodegeneration
affected brains using both immunohistochemistry and
immunofluorescence. Due to intravascular RBCs contamination,
they considered Western blot technique not useful to analyze
minor modifications of hemoglobin in nervous system (Ferrer
et al., 2011).
To confirm this idea, we analyzed all our samples and we
observed that even small amount of blood-derived RNA showed
high levels of both Hb and reference genes. Thus, we decided to
include the CT-value ofALAS2 in1CT formula, for both patients
and control samples. In particular, we subtracted the CT value
of ALAS2 to the canonical 1CT, normalizing the expression of
both hemoglobin (HBB and HBA1/2) and housekeeping genes
(GAPDH, ACTB, RPL19, B2M) for erythrocytes content. The
resulting “blood normalized” 11CT was used to calculate the
fold change.
Re-analyzing RT-qPCR data with this improved method,
we observed a strong down-regulation of both hemoglobin
gene transcripts in patients with Alzheimer’s disease.
Similarly, we observed reduced hemoglobin protein levels
with immunofluorescence staining, further corroborating the
robustness of our analysis.
Regarding prion diseases groups, dysregulated HBB and
HBA1/2 transcript levels followed different trends depending on
the disease type. Genetic and sporadic prion diseases affected
patients did not exhibit any alteration for what concerns
hemoglobin genes expression, suggesting that prion infection
may exert a limited impact on the transcriptional machinery
involved in neuronal hemoglobin expression.
However, the analysis of HBB and HBA1/2 mRNA levels
in acquired prion diseases patients revealed some differences,
suggesting that exogenous prions might exert an impact on
Hb metabolism. In particular, while an up-regulation for both
hemoglobin genes was evident in vCJD patients (statistically
significant for HBA1/2 expression), iCJD group exhibited a
down-regulated Hb gene expression (statistically significant for
HBB expression).
One explanation for the different expression levels reported
between the two Hb chains could depend on primers pair
designed for HBA1/2 transcripts, which bind both the human α-
2 (HBA2) and α-1 (HBA1) coding sequences. Therefore, being
primers pair for α-globin genes able to recognize two different
transcripts, the signal contribution given by qPCR amplification
might be different between HBA1/2 and HBB. Considering also
the fact that HBA1 and HBA2 could be differently regulated,
all these observations might explain the lack of correlation seen
in some prion groups in the expression trend between the two
hemoglobin chains genes. Furthermore, although it has been
reported that α and β subunits function as a tetramer both in
erythrocytes and neurons (Russo et al., 2013), they may also act
independently one from another. Indeed, while Hb α regulates
NO release in vascular endothelial cells independently of Hb β
(Straub et al., 2012), tetramer of β-globin chains (HbH) were
shown to possess a higher binding affinity for O2 than classical
α2β2 hetero-tetramers (Bellelli et al., 2006). The different levels
of HBB and HBA1/2 dysregulation observed in some diseases
groups could be explained also by the independent functions
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FIGURE 7 | Hemoglobin beta-chain in the frontal cortex of control subject (A–C), Alzheimer’s disease (D–F) and sCJD (G–I). Immunofluorescence and confocal
microscopy for hemoglobin B chain (A,D,G) and nuclei (B,E,H) showing reduced hemoglobin immunoreactivity in neurons of AD and sCJD (F, I merge) compared to
control (C merge). Nuclei stained with DRAQ5TM. Bar = 50µm.
adopted by the two hemoglobin chains in brain tissue or even
in different cell populations, given that we analyzed RNA from
whole frontal cortex without distinguishing white from gray
matter, where differential expression of Hb genes has been
reported (Mills et al., 2015).
Nevertheless, our results suggest that brain hemoglobin
dysregulation is different among patients suffering from various
prion diseases, supporting a prion strain-specific on hemoglobin
gene expression.
In particular, this finding suggest that hemoglobin genes could
be used as TSEs strain determinants (Booth et al., 2004b) or
may contribute to strain-specific neurodegenerative processes
(Skinner et al., 2006).
Indeed, PrPSc to PrPC binding is necessary to produce
new misfolded isoforms, therefore it is plausible that different
PrPSc strains could activate specific PrPC molecular scaffolding
partners. In this way, a variety of signaling pathways could
be switched on/off, leading to the transcriptional inhibition or
activation of many genes, among which hemoglobin coding
ones.
In this view, it seems that BSE prion strain (as in vCJD group)
is responsible for an up-regulation of hemoglobin genes. Our
findings seem to be in contrast with previous results in BSE-
infected macaques, where both HBB and HBA1/2 were strongly
down-regulated.
However, this discrepancy could be explained by the fact
that, even if the gene expression analysis in macaques brain
was performed using ALAS2 CT to exclude any major effect
of potential blood contamination, RT-qPCR data analysis were
not assessed using the “blood normalized” 2−11CT method. Our
findings imply that even subtle presence of blood hemoglobin
transcripts, not excluded using a CT cutoff value for ALAS2,
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FIGURE 8 | Hemoglobin alpha-chain in the frontal cortex of control subject (A–C), Alzheimer’s disease (D–F) and sCJD (G–I). Immunofluorescence and confocal
microscopy for hemoglobin α-chain (A,D,G) and nuclei (B,E,H) showing hemoglobin immunoreactivity in neurons of AD patients (F, I merge) compared to control (C,
merge). Nuclei stained with DRAQ5TM. Bar = 50µm.
could influence brain hemoglobin gene expression. This suggests
that small blood traces may have probably influenced Hb
genes expression analysis in macaque brains. Another source
of hemoglobin transcript contamination could be endothelial
cells where HBA1/2 expression has been reported (Straub
et al., 2012). However, neither AD nor prion diseases are
known for alterations in the number of vessels in comparison
to age-matched healthy subjects, therefore the influence of
endothelial Hb should be similar across controls and patients.
Despite this, we investigated the expression levels of two
commonly known specific endothelial genes, CD34 and KDR
(Vascular Endothelial Growth Factor Receptor 2) and we did not
observe any significant difference between controls and patients
(Figure 3).
Moreover, opposite results concerning hemoglobin expression
between vCJD patients and intracranially BSE-infected macaques
may depend on the different routes through which they have been
exposed to BSE. Indeed, the single macaque which was orally
challenged with BSE (B6) showed amarked up-regulation ofHBB
transcript, reinforcing this hypothesis. We can hypothesize that a
combination of strain and route of infection could be responsible
for specific hemoglobin genes alterations. In particular, brain-
directed BSE inoculation in macaques could produce metabolic
insults resulting in a reduction of hemoglobin transcription,
in a similar way through which aggregating protein deposits
are responsible for a reduced neuronal hemoglobin expression
(Ferrer et al., 2011).
It remains to clarify the molecular events through which
oral BSE prion strain consumption elicits the up-regulation
of hemoglobin gene (statistical significant for HBA1/2) in
CNS of vCJD patients. One possible explanation could come
from some neuronal hemoglobin behavioral effects that were
recently shown overexpressing both α- and β-globin chains in
mice substantia nigra. Indeed, upon Hb overexpression, mice
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presented motor skill learning impairments (Codrich et al.,
2017), suggesting a possible role of Hb in neuronal damage
occurring in substantia nigra of PD affected patients. In a similar
way, the impaired coordination commonly observed in vCJD
cases (Spencer et al., 2002), could derive from the aggregation
of Hb, probably originating from its transcriptional up-regulated
levels.
Furthermore, the Hb ability to bind to Aβ, enhancing its
aggregation (Wu et al., 2004; Chuang et al., 2012), suggests that
a similar interaction could be hypothesized between hemoglobin
and BSE prion strain. In particular, up-regulated Hb levels could
increase the aggregation of this peculiar prion strain, facilitating
the development of vCJD.
One other cause responsible for the lack of clarity concerning
hemoglobin genes dysregulation in some patients groups could
originate from the mixed cell populations present in frontal
cortex tissue from which RNA was extracted. This hypothesis is
corroborated by previous findings which showed up-regulated
hemoglobin genes (HBB, HBA1, HBA2) expression when white
matter was compared with gray matter of MSA patients (Mills
et al., 2015).
We can hypothesize that in AD, and probably also in iCJD and
sCJD, when down-regulated Hb is not available for this function,
cells get damaged by the defective oxygen homeostasis (Barbisin
et al., 2014).
Since hemoglobin is the most abundant source of peripheral
iron in humans, one clear implication of its dysregulation would
be iron homeostasis alteration.
Iron metabolism alterations were observed in the central
nervous system of many neurodegenerative disease affected
patients. The decrease in Hb expression found in AD, iCJD,
and sCJD could determine an increased amount of free iron
which is highly toxic due to the generation of reactive oxygen
species via the Fenton and Haber-Weiss reactions (Singh et al.,
2014).
For prion diseases, the released iron would be bound by
ferritin, creating a redox-active and cytotoxic complex with
PrPSc, ultimately lead to iron imbalance (deficiency phenotype)
and to an increase of PrPSc toxic species (Singh et al., 2014)
supporting the progression of the disease.
Even though only AD and sCJD cases were available for
immunofluorescence and confocal microscopy, in general this
analysis confirms the results observed at the transcriptional
level. As already mentioned, Hb α and Hb β are probably
regulated in different ways. While in AD samples both proteins
and transcripts are consistently down-regulated, sCJD cases
are more intriguing. Indeed, while Hb β is barely detectable,
Hb α is still present in many cells. Therefore it could be
that protein expression does not exactly reflect transcription
in sCJD. However, in a single case of sCJD we observed
a great Hb α immunoreactivity in astrocytes (Figures S10,
S11), supporting the hypothesis of a different regulation
and/or expression of both chains in different cell types,
particularly neurons and astrocytes. This may also explain the
lack of significant dysregulation of Hb transcripts in sCJD
samples, given that the qPCR results come from mixed cell
populations.
Our results suggest that brain hemoglobin could be an
attractive candidate marker of neurodegeneration. Dysregulated
levels of a protein with putative roles in O2 brain homeostasis and
balance of redox system could be a sign of functional alterations
occurring in brain of patients affected by neurodegenerative
diseases. Moreover, through gene expression profiling is possible
to identify specific molecular targets able to discriminate among
different infectious agents (Booth et al., 2004a). In this context,
marked differences in hemoglobin genes expression between
sCJD and AD patients could represent a specific response of
affected brain tissue to different neurodegeneration causing
proteins deposits. In particular, our findings suggest that Aβ is
able to activate molecular response pathway, which ultimately
leads to a strong down-regulation of both hemoglobin gene
expression.
CONCLUSIONS
Hemoglobin gene expression alterations occurring in
neurodegeneration-affected brains are not well documented
and their role in disease remains elusive. In our gene expression
analysis we propose a correction method for the presence
of blood in tissue samples. These results strongly suggest
that the neurodegenerative-specific hemoglobin mRNA level
dysregulations can be associated to neuronal/glial populations.
Future studies may discriminate in which cell types these
dysregulations occur.
We can infer that only the BSE prion strain acquired via a
peripheral route, as in vCJD patients, is able to cause an up-
regulation of HBA1/2 gene expression, while the various strains
associated with hGH-iatrogenic CJD cases seem to be responsible
for down-regulation ofHBB gene expression. Other prion strains
causing human genetic TSEs, sCJD strains, seem not to be
responsible for any major Hb gene dysregulation. These findings
suggest a strain-specific involvement of Hb genes in response to
prion accumulation in affected brains.
Given the diverse tropism characterizing different prion
strains, additional Hb gene expression analysis should be
performed to understand how other brain regions are affected by
hemoglobin dysregulation.
These alterations occur as either early or late consequence
of the disease and may represent a susceptibility factor that
influences the onset of the pathology.
Most importantly, a significant down-regulation of both HBB
and HBA1/2 is evident in AD patients. Given the high number
of clinical phenotypic similarities and comparable age of disease
onset between sCJD and AD patients, the difference in Hb
gene expression open the possibility to develop a diagnostic test
in order to perform differential diagnosis. Validation of these
results in more readily accessible tissues, such as CSF or nasal
brushing samples, could be helpful for clinicians in the correct
interpretation of neurodegenerative symptoms.
Even though a clear correlation between hemoglobin gene
expression and neurodegeneration has not yet been defined,
taken together our findings strongly suggest a brain hemoglobin
involvement in neurodegenerative processes.
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